CIM
MRNA icon

Chiron Investment Management’s Moderna MRNA Stock Holding History

Chiron Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$7.22M Buy
+69,118
New +$6.99M 1% 49

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Chiron Investment Management's MRNA Position: Q4 2020 in Review

Chiron Investment Management opened a new position in Moderna (MRNA) in Q4 2020: 69,118 shares worth $7.22M. The stake represents 1% of the portfolio and ranks #49 among its holdings.

717 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

  • Chiron Investment Management held 69,118 shares of Moderna worth $7.22M as of Q4 2020.
  • Moderna was a new Chiron Investment Management position in Q4 2020.
  • Moderna made up 1% of Chiron Investment Management's portfolio in Q4 2020, its #49 holding.
  • 717 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on Chiron Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.